Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial position.

In October 2024, Lutris successfully completed enrollment in the international phase 2 trial of LUT014 in patients with metastatic colorectal cancer (mCRC) treated with EGFRi therapy who develop ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...